Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Brunangelo Falini is active.

Publication


Featured researches published by Brunangelo Falini.


The American Journal of Surgical Pathology | 2001

Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells?

L De Leval; Judith A. Ferry; Brunangelo Falini; Margaret A. Shipp; Nancy Lee Harris

Primary mediastinal large B-cell lymphomas (LBCLs) constitute a unique subtype of diffuse LBCLs, with distinct clinical, immunophenotypic, and morphologic features. These lymphomas are thought to originate from the thymus, and it has been hypothesized that they derive from a population of B lymphocytes normally present in the thymic medulla. Most diffuse LBCLs harbor somatic mutations in their immunoglobulin genes, suggesting that they have been exposed to the germinal center. To investigate the possible relationship of mediastinal LBCLs to germinal center B cells, we analyzed the expression of bcl-6 and CD10 in 19 mediastinal LBCLs, using an immunoperoxidase technique on formalin-fixed tissue. We found that 19 of 19 (100%) mediastinal LBCLs were bcl-6+ and 6 of 19 (32%) mediastinal LBCLs were CD10+. Because mediastinal LBCLs usually lack BCL-6 gene rearrangement or mutations, expression of bcl-6 and CD10 in these tumors tends to support a germinal center derivation.


Archive | 1995

The Reed-Sternberg Cell and the CD30 Antigen

Horst Dürkop; Ute Latza; Brunangelo Falini; Gianpaolo Nadali; Giovanni Pizzolo; Harald Stein

The tumour cells of Hodgkin’s disease (HD), called Reed-Sternberg and Hodgkin cells (H-RS cells) are, in conjunction with an admixture of non-malignant cells of various types, pathognomonic for HD. In most cases, the H-RS cells account for less than 5% and in some cases for less than 1% of the total tumour mass. In classical cases, the H-RS cells are large cells with bi-lobed or poly-lobed nuclei so that the cells appear binucleated or multinucleated. It is possible that, in some cases, bona fide multinucleation does actually occur. The nuclear membrane is thick and sharply defined, and there is a very large, variously shaped, acidophilic central nucleolus surrounded by a clear halo. In the most typical example of the H-RS cell, the two nuclear lobes face each other. The non-malignant counterpart of these cells is still a matter of debate. In most cases they react with the lymphoid surface markers CD30 (Schwab et al., 1982; Stein et al., 1985) and CD70 and in some cases with CDw75, CD3, T-cell receptor s chain (TcRs) (Dallenbach and Stein, 1989), J-chain (Stein et al., 1986) and CD20. These data, as well as the detection of immunoglobulin and T-cell receptor (TcR) rearrangements by Southern blot in some instances (Herbst et al., 1989), provide evidence for a lymphoid origin of these tumour cells. In particular, Dallenbach and Stein (1989) were able to detect TcRs on the H-RS cells of 24 of 65 cases and CD20 on the H-RS cells of 12 of 65 cases. Recently, support of these data came from Tamaru et al. (1994) who reported that in 67% of HD cases with B-cell-antigen positive H-RS cells, clonal VDJ rearrangements of the immunoglobulin heavy chain (IgH) gene were detectable; no VDJ rearrangements were detected in cases with T-cell antigen-positive H-RS cells.


The American Journal of Surgical Pathology | 1994

Nodular lymphocyte predominance Hodgkin's disease. A distinct clinicopathological entity

David Y. Mason; Peter M. Banks; John K.C. Chan; Michael L. Cleary; Georges Delsol; Chris de Wolf Peeters; Brunangelo Falini; Kevin C. Gatter; Thomas M. Grogan; Nancy Lee Harris; Peter G. Isaacson; Elaine S. Jaffe; Daniel M. Knowles; H. Konrad Miiller-hermelink; Stefano Pileri; Elisabeth Ralfkiaer; H. Stein; Roger A. Warnke


Haematologica | 1999

Genomic instability and recurrent breakpoints are main cytogenetic findings in Hodgkin's disease

Daniela Falzetti; Barbara Crescenzi; C Matteuci; Brunangelo Falini; M F Martelli; H. Van den Berghe; C. Mecucci


Annals of Oncology | 1997

Bcl-6 protein expression in normal and neoplastic lymphoid tissues

Brunangelo Falini; M. Fizzotti; Stefano Pileri; A. Liso; L. Pasqualucci; L. Flenghi


Archive | 1993

Antibody/radioisotope conjugate for tumor diagnosis and/or therapy

Harald Stein; Brunangelo Falini


Blood | 1998

The cryptic inv(2)(p23q35) defines a new molecular genetic subtype of ALK-positive ALCL

Iwona Wlodarska; C. De Wolf-Peeters; Brunangelo Falini; Gregor Verhoef; Stephan W. Morris; Anne Hagemeijer-Hausman; Herman Van den Berghe


Archive | 1992

New immuno-toxin contg. CD30 monoclonal antibody - is coupled to type 1 ribosome inactivating protein toxin, for selective elimination of CD30 cells, esp. treatment of Hodgkins disease

Brunangelo Falini; Firenzo Prof Dr Med Stirpe; Harald Prof Dr Med Stein


Archive | 2012

Hairy Cell Leukemia Biomarkers and Methods of Using Same

Brunangelo Falini; Raul Rabadan; Enrico Tiacci


Archive | 2012

Methods of Detecting BRAF Mutations in Cancer

Enrico Tiacci; Brunangelo Falini

Collaboration


Dive into the Brunangelo Falini's collaboration.

Top Co-Authors

Avatar

Stefano Pileri

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Harald Stein

Free University of Berlin

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge